Search results
Merck reports data from Phase III gastric cancer treatment trial
Clinical Trials Arena via Yahoo Finance· 8 hours agoMerck (MSD) has announced the final analysis findings from the Phase III KEYNOTE-811 clinical trial...
Is Merck Stock Fully Valued At $130?
Forbes· 1 day agoMerck (NYSE: MRK) recently reported its Q1 results, with revenues and earnings exceeding our estimates. The growth was primarily driven by higher sales...
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 11 minutes agoMeanwhile, Moderna is expanding its efforts in cancer treatment. The company is partnered with Merck...
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 23 hours agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats...
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Zacks via Yahoo Finance· 2 hours agoModerna did not record any grant and collaboration revenues during the quarter, compared to $34...
Merck KGaA's Dividend Analysis
GuruFocus.com via Yahoo Finance· 3 days agoMerck KGaA (MKKGY) recently announced a dividend of $0.47 per share, payable on 2024-05-09, with the ex-dividend date set for 2024-04-29. As investors...
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $143.00
ETF DAILY NEWS· 3 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) had its target price boosted by Truist Financial from $142.00 to $143.00 in a research report released on Friday, Benzinga reports ...
Moderna (MRNA) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 16 minutes agoDuring the first quarter, we presented substantial clinical progress during our vaccine date with exciting data on EBV, VZV, and norovirus. In addition,...
Merck reports promising V116 vaccine trial results By Investing.com
Investing.com· 3 days agoMerck & Co. (NYSE: MRK) has presented new data from its Phase 3 STRIDE-10 trial of V116, an...
